Aarthi Jayanthan
About Aarthi Jayanthan
Aarthi Jayanthan is the Chief Operating Officer with a Ph.D. in molecular cancer biology from the University of Calgary, specializing in developing therapies for childhood cancer and leading significant advancements in cancer biomarkers and drug resistance models.
Chief Operating Officer
Aarthi Jayanthan currently holds the position of Chief Operating Officer. In this role, she oversees various operational functions, ensuring that the company's day-to-day activities align with its strategic goals. Her responsibilities likely include managing internal teams, optimizing processes, and driving operational efficiency. As a COO, Aarthi's leadership is instrumental in guiding the organization's growth and maintaining its competitive position in the market.
Ph.D. in Molecular Cancer Biology and Cell Signaling
Aarthi Jayanthan earned her Ph.D. from the University of Calgary, where she specialized in molecular cancer biology and cell signaling. Her academic focus was on developing novel therapies for children with cancer. This involved in-depth research and experimentation aimed at understanding the cellular mechanisms underlying cancer and identifying potential therapeutic targets. Her work has contributed significantly to advancing the field of pediatric oncology.
Preclinical Studies and Clinical Trials
Aarthi Jayanthan has contributed to numerous preclinical studies that investigate experimental therapies for childhood cancers such as leukemia, AT/RT, neuroblastoma, and lymphoma. Her work has been pivotal in the development and validation of new treatment approaches. Additionally, she has provided crucial support in Phase I clinical trials sponsored by the Pediatric Oncology Experimental Therapeutics Investigators Consortium (POETIC), facilitating the translation of experimental therapies from the lab to clinical settings.
Inventor on Several Issued Patents
Aarthi Jayanthan is a contributing inventor of several issued patents. These patents likely cover innovative therapeutic methods, diagnostic tools, or drug formulations. Her involvement in patent development underscores her role in advancing cutting-edge research and translating scientific discoveries into tangible medical innovations.
Biomarker and Drug Resistance Research
Aarthi Jayanthan led the co-development of RSK2 CDxV from pre-clinical method development to a CAP/CLIA certified clinical stage assay in collaboration with Roche Ventana. She advanced surrogate biomarker programs utilizing gene expression profiling on the Nanostring platform. Additionally, she was instrumental in developing the first blood biomarker assay for RSK inhibitors and models of drug resistance to breast cancer therapeutics, including paclitaxel and CDK4/6 inhibitors. Her research also identified novel drug combinations for PMD-026, aimed at enhancing life-cycle development post-regulatory approval.